Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T16:12:45.292Z.
Calculation as of: 2026-10-06T16:12:45.292Z.
Quote observation: 2026-10-06T16:10:13.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fa669979e2b3f995ef920df13c3a539cab2f3704a4556e475e3dd75e53b0e3a2
PE RATIO
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kestra Medical Technologies, Ltd. (KMTS) | $1.61B | N/A | N/A | N/A | N/A |
| Omnicell, Inc. (OMCL)vs › | $1.59B | 41.51 | 225.17 | 171.32 | 153.65 |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.62B | 15.44 | 29.99 | 47.18 | 47.18 |
| Ocular Therapeutix, Inc. (OCUL)vs › | $1.63B | N/A | N/A | N/A | N/A |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.65B | N/A | N/A | N/A | N/A |
| uniQure N.V. (QURE)vs › | $1.53B | N/A | 3.39 | 3.43 | 3.43 |
| Innoviva, Inc. (INVA)vs › | $1.54B | 5.09 | 13.44 | 25.81 | 17.64 |
| Nutex Health, Inc. (NUTX)vs › | $1.53B | 8.78 | 9.48 | 9.58 | 16.69 |
| Personalis, Inc. (PSNL)vs › | $1.70B | N/A | N/A | N/A | N/A |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.70B | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$27.47
Forward EPS (Est.)
$-2.45
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
